Connor, Clark & Lunn Investment Management (CC&L)’s NovoCure NVCR Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $10.9M | Buy |
610,714
+75,965
| +14% | +$1.35M | 0.04% | 378 |
|
|
2025
Q1 | $9.53M | Buy |
534,749
+96,977
| +22% | +$1.73M | 0.04% | 325 |
|
|
2024
Q4 | $13M | Buy |
437,772
+11,509
| +3% | +$343K | 0.06% | 258 |
|
|
2024
Q3 | $6.66M | Buy |
426,263
+59,608
| +16% | +$932K | 0.03% | 373 |
|
|
2024
Q2 | $6.28M | Buy |
366,655
+52,278
| +17% | +$896K | 0.03% | 376 |
|
|
2024
Q1 | $4.91M | Sell |
314,377
-95,223
| -23% | -$1.49M | 0.02% | 434 |
|
|
2023
Q4 | $6.12M | Buy |
409,600
+761
| +0.2% | +$11.4K | 0.03% | 369 |
|
|
2023
Q3 | $6.6M | Buy |
408,839
+339,610
| +491% | +$5.48M | 0.03% | 329 |
|
|
2023
Q2 | $2.87M | Buy |
69,229
+59,978
| +648% | +$2.49M | 0.01% | 510 |
|
|
2023
Q1 | $556K | Buy |
+9,251
| New | +$556K | ﹤0.01% | 856 |
|
|
2022
Q3 | – | Sell |
-12,750
| Closed | -$886K | – | 1210 |
|
|
2022
Q2 | $886K | Buy |
+12,750
| New | +$886K | 0.01% | 648 |
|